Caledonia Mining Corporation Plc: Results of Annual General Meeting ST HELIER, Jersey, May 07, 2024 (GLOBE NEWSWIRE) -- Caledonia Mining Corporation Plc ("the Company") (NYSE American, AIM and VFEX: CMCL) announces the results of its annual general meeting of shareholders (the “AGM”) held at St Helier, Jersey today. The total number of shareholders present in person or by proxy at the AGM was 96, representing 62.28% of the Company’s outstanding voting shares. The table below shows the proxy votes received on resolutions 1(a) to 1(h), which were duly passed by a show of hands, to rea...
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) Anticipates CHMP opinion for pegcetacoplan in GA no later than July 2024On track to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in mid-2024Cash and cash equivalents of $325.9 million as of March 31, 2024; projected revenues and cash expected to be sufficient to fund operations for foreseeable futureMan...
HOUSTON--(BUSINESS WIRE)-- Ranger Energy Services, Inc. (NYSE: RNGR) (“Ranger” or the “Company”) announced today its results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights – Revenue of $136.9 million, a 13% decrease from $157.5 million in first quarter 2023 driven by declines in wireline completions and ancillary services – High specification rig revenue of $79.7 million, a 3% increase from $77.5 million in first quarter 2023 with additional growth anticipated in future quarters – Net loss of $0.8 million, or negative $0.03 per fully diluted share, a decrease...
MGP Names New Distilling Solutions Vice President Industry veteran Paul Lux joins company to continue execution of strategy for the segment ATCHISON, Kan., May 06, 2024 (GLOBE NEWSWIRE) -- MGP Ingredients, Inc., (MGPI: Nasdaq), a leading producer of branded and distilled spirits as well as food ingredient solutions, has named Paul Lux as Vice President of Sales for the Distilling Solutions segment, effective today. Lux will work closely with Amel Pasagic, Chief Commercial Officer, on the continued execution of MGP’s strategy for the Distilling Solutions segment. “Paul knows how we oper...
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Bank of America Securities Healthcare Conference on Tuesday, May 14, 2024, at 8:00 a.m. PT. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s . A replay of the webcast will be available for approximately 90 days following the event. About Apel...
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of May 1, 2024 an equity inducement award to Melita Sun Jung, the Company’s new Chief Business Officer, under the terms of the 2022 Employment Inducement Award Plan, a...
MGP Ingredients Reports First Quarter 2024 Results Q1 results in line with expectations; Reiterates annual guidance ATCHISON, Kan., May 02, 2024 (GLOBE NEWSWIRE) -- MGP Ingredients, Inc. (Nasdaq: MGPI), a leading provider of branded and distilled spirits as well as food ingredient solutions, today reported results for the first quarter ended March 31, 2024. 2024 first quarter consolidated results compared to 2023 first quarter: Due to the Atchison distillery closure, sales decreased 15% to $170.6 million. Excluding the impact of the Atchison distillery in both periods, consolidated sa...
MGP Ingredients Declares $0.12 Quarterly Dividend ATCHISON, Kan., May 02, 2024 (GLOBE NEWSWIRE) -- MGP Ingredients, Inc. (Nasdaq: MGPI), a leading provider of branded and distilled spirits as well as food ingredient solutions, today announced that its board of directors has declared a quarterly dividend of $0.12 cents per share of common stock. The dividend is payable on May 31, 2024 to stockholders of record as of May 17, 2024. About MGP Ingredients, Inc.MGP Ingredients, Inc. (Nasdaq: MGPI) is a leading producer of premium branded and distilled spirits, as well as food ingredient solut...
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that 14 abstracts, 11 of which are oral presentations, will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5 - 9 in Seattle. The data continue to reinforce the robust efficacy and safety profile of SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degene...
CVRx Reports First Quarter 2024 Financial and Operating Results MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024. Recent Highlights Total revenue for the first quarter 2024 was $10.8 million, an increase of 35% over the prior year quarterU.S. Heart Failure (HF) revenue for the first quarter of 20...
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer. "I am delighted to welcome Scott to Akero. His depth of experience leading drug manufacturing for both national and multi-national biopharmaceutical organizations enriches our company with an invaluable perspective during the late...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.